- Home
- Editorial
- News
- Practice Guidelines
- Anesthesiology Guidelines
- Cancer Guidelines
- Cardiac Sciences Guidelines
- Critical Care Guidelines
- Dentistry Guidelines
- Dermatology Guidelines
- Diabetes and Endo Guidelines
- Diagnostics Guidelines
- ENT Guidelines
- Featured Practice Guidelines
- Gastroenterology Guidelines
- Geriatrics Guidelines
- Medicine Guidelines
- Nephrology Guidelines
- Neurosciences Guidelines
- Obs and Gynae Guidelines
- Ophthalmology Guidelines
- Orthopaedics Guidelines
- Paediatrics Guidelines
- Psychiatry Guidelines
- Pulmonology Guidelines
- Radiology Guidelines
- Surgery Guidelines
- Urology Guidelines
Addition of diabetes drug Metformin improves survival in lung cancer patients: JAMA Oncology
Mexico: The diabetes drug metformin apart from lowering blood sugar in type 2 diabetes patients has been previously shown to have varied benefit in other health conditions as well. Now, a recent study has shown benefit of the drug for lung cancer patients.
According to results of the phase 3 study, published in the JAMA Oncology journal, the addition of metformin in patients with EGFR (epidermal growth factor receptor)-mutated lung adenocarcinoma increased progression-free and overall survival sans any significant increase in adverse events.
Metformin hydrochloride is emerging as a repurpose anticancer drug. The drug has shown to improve outcomes across a wide variety of neoplasms, including lung cancer in preclinical and retrospective studies.
Oscar Arrieta, Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico, and colleagues assessed the progression-free survival in patients with advanced lung adenocarcinoma who received EGFR–TKIs (tyrosine kinase inhibitors) therapy plus metformin compared to those who received EGFR-TKIs alone.
In the study, 139 patients (Mean age: 59.4 and 65.5% were female) were randomized to receive standard EGFR-TKIs (n=70) or EGFR-TKIs plus metformin 500 mg twice daily (n=69) from March 2016 to December 2017.
All the participants had histologically confirmed stage IIIb/IV lung adenocarcinoma with an activating EGFR mutation and measurable lesions. All were naïve to EGFR-TKIs, had an Eastern Cooperative Oncology Group performance status of 2 or less, and a life expectancy of at least 12 weeks. Median follow-up was 16.9 months.
Also Read: Metformin prevents endometriosis in breast cancer patients
Key findings include:
- The median PFS was significantly longer in the EGFR-TKIs plus metformin group compared with the EGFR-TKIs group (13.1 months compared with 9.9 months).
- The median overall survival was also significantly longer for patients receiving combination therapy: 31.7 months vs 17.5 months.
- Patients allocated to receive added metformin were more likely to respond to EGFR-TKI therapy: 71.0% vs 54.3%.
- The combination lowered the risk of non-response, achieving an objective response rate of 0.48.
- The addition of metformin was the only factor independently associated with better overall survival, decreasing the risk of death by half.
- Grade 3/4 adverse events in both arms were similar in frequency in both arms and included diarrhoea, rash, nausea, and mucositis.
Also Read: Diabetes drug Metformin may promote brain repair after stroke in females
"To our knowledge, this is the first study to prospectively show that the addition of metformin to standard EGFR-TKIs therapy in patients with advanced lung adenocarcinoma significantly improves PFS. These results justify the design of phase 3, placebo-controlled study," wrote the authors.
To read the complete study log on to doi:10.1001/jamaoncol.2019.2553
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd